NeurologyLive® Friday 5 — November 6, 2026

Welcome to NeurologyLive^®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive's widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

Don’t have time to read or watch a full video interview? Click here to check out our shorts!

Click the read more or watch now buttons for more details and information about each highlight.

1: Assessing Long-Term Disease Control With Nipocalimab in Pediatric Generalized Myasthenia Gravis: Jonathan Strober, MD

In a recent AANEM 2026 interview, Jonathan Strober, MD, director of the Pediatric Neuromuscular Program at UCSF Benioff Children’s Hospital San Francisco, discussed 2-year findings from the phase 2/3 VIBRANCE-MG study of nipocalimab in adolescents with generalized MG. [WATCH TIME: 6 minutes]

2: Elizabeth Spurgeon, MD, on Lifestyle Interventions as an Adjunct to Epilepsy Care

In a recent Q&A interview, Elizabeth Spurgeon, MD, an epileptologist at the Cleveland Clinic Epilepsy Center, discussed findings from a recently published study of lifestyle interventions in epilepsy and why these approaches should complement rather than replace antiseizure medications.

3: Recapping the 2026 STARS Conference and the Push for Interdisciplinary Stuttering Care: Gerald Maguire, MD

In a recent video interview, Gerald Maguire, MD, president and founder of the Stuttering Treatment and Research Society (STARS), discussed highlights from the society's 2026 conference, its new interdisciplinary consensus guidelines, and the next steps for stuttering care. [WATCH TIME: 5 minutes]

4: NeuroVoices: Cindy Zadikoff, MD, MSc, on the FDA Approval of Tavapadon for Parkinson Disease

In a recent Q&A interview, Cindy Zadikoff, MD, MSc, executive medical director of Clinical Development Neuroscience at AbbVie, discussed the FDA approval of tavapadon, the first D1/D5 dopamine agonist for Parkinson disease, including the supporting TEMPO trial data and safety considerations.

5: Examining Sustained Disability Signals With Vidofludimus Calcium in Progressive MS: Robert J. Fox, MD

In a recent MSToronto 2026 interview, Robert J. Fox, MD, staff neurologist at the Mellen Center for Multiple Sclerosis at Cleveland Clinic, discussed open-label extension data from the phase 2 CALLIPER trial of vidofludimus calcium in progressive multiple sclerosis. [WATCH TIME: 6 minutes]